Jubilant Pharmova LimitedQ1 FY27 Results & Financial Update
Jubilant Pharmova Limited: Q1 FY27 consolidated results and company financials – revenue ₹2,229.40 Cr, PAT ₹56.40 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Jubilant Pharmova price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Jubilant Pharmova Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the quarter ended June 30, 2026, Jubilant Pharmova reported consolidated total revenue from operations of INR 2,229.4 crore and total income of INR 2,249.3 crore.
Profit before tax (PBT) for the quarter stood at INR 86.4 crore, while profit after tax (PAT) reached INR 56.4 crore, reflecting basic and diluted earnings per share of INR 3.57.
The Radiopharma segment emerged as the largest revenue contributor at INR 1,022.1 crore with a segment result of INR 78.0 crore, demonstrating steady demand across its core nuclear medicine portfolio.
The CDMO Sterile Injectables division recorded revenue of INR 519.8 crore alongside a segment result of INR 7.3 crore, while the Allergy Immunotherapy segment generated revenue of INR 214.4 crore and a segment result of INR 63.5 crore.
Contract Research, Development and Manufacturing Organisation (CRDMO) operations delivered stable performance with revenues of INR 325.8 crore and segment profit of INR 35.6 crore.
The Generics segment experienced profitability pressure, posting a segment loss of INR 10.1 crore on revenues of INR 173.4 crore, and Proprietary Novel Drugs registered a segment loss of INR 7.6 crore.
Total expenses for the quarter stood at INR 2,162.9 crore, driven by employee benefit expenses of INR 753.5 crore, cost of materials consumed at INR 638.3 crore, and depreciation and amortization charges of INR 127.3 crore.
01 · Business model
What does Jubilant Pharmova do?
Jubilant Pharmova Limited is a global pharmaceutical and life sciences company operating across multiple specialized business verticals, including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation (CDMO) for sterile injectables, Contract Research, Development and Manufacturing Organisation (CRDMO), Generics, and Proprietary Novel Drugs.
The company serves global markets, particularly North America, Europe, and other international jurisdictions, delivering critical diagnostic and therapeutic radiopharmaceuticals, allergy relief treatments, and advanced contract manufacturing and research services.
Its economic model relies on high-barrier scientific capabilities, regulatory-compliant manufacturing infrastructure, and specialized R&D partnerships that support long-term biopharmaceutical and clinical pipelines.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹2,229.40 Cr |
| Total income | ₹2,249.30 Cr |
| Profit before tax | ₹86.40 Cr |
| Profit after tax | ₹56.40 Cr |
| EPS | ₹3.56 |
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Radiopharma led segment revenues at INR 1,022.1 crore for the quarter, supported by ongoing global demand for diagnostic and therapeutic nuclear medicine products.
Contract Development and Manufacturing Organisation for Sterile Injectables brought in INR 519.8 crore, reflecting client manufacturing commitments.
Contract Research, Development and Manufacturing Organisation contributed INR 325.8 crore in quarterly revenue.
Allergy Immunotherapy added INR 214.4 crore, while Generics contributed INR 173.4 crore to consolidated operational revenue.
What drove margins
Cost of materials consumed was INR 638.3 crore, purchases of stock-in-trade stood at INR 86.9 crore, and inventory changes reduced expenses by INR 23.5 crore.
Employee benefits expense formed a significant operational outlays at INR 753.5 crore, while other expenses totaled INR 479.2 crore.
Finance costs for the quarter were registered at INR 54.2 crore, and depreciation, amortisation, and impairment expenses totaled INR 127.3 crore.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Generated revenue of INR 1,022.1 crore and a segment result of INR 78.0 crore, with segment assets standing at INR 3,857.2 crore.
Recorded revenue of INR 214.4 crore and a segment result of INR 63.5 crore, backed by segment assets of INR 624.1 crore.
Reported revenue of INR 519.8 crore and a segment result of INR 7.3 crore, maintaining the largest segment asset base at INR 6,355.1 crore.
Posted revenue of INR 325.8 crore and segment profit of INR 35.6 crore, with assets of INR 1,766.9 crore.
Delivered revenue of INR 173.4 crore with a segment loss of INR 10.1 crore, and segment assets of INR 1,178.7 crore.
Recorded a segment loss of INR 7.6 crore with zero operating revenue for the quarter.
05 · Reported developments
What changed operationally
The Radiopharma division sustained solid segment earnings of INR 78.0 crore on robust top-line performance.
Allergy Immunotherapy maintained strong profitability relative to its revenue base, delivering a segment result of INR 63.5 crore.
06 · Pressure points & risks
What is not going smoothly
The Generics division faced profitability headwinds, registering a segment loss of INR 10.1 crore during the quarter.
Proprietary Novel Drugs continued to incur operational segment losses of INR 7.6 crore without recorded commercial revenue.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Approval and Review
The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors on August 10, 2026.
08 · Key Q&A
The quarter, answered directly
What does Jubilant Pharmova do?
Jubilant Pharmova Limited is a global pharmaceutical and life sciences company operating across multiple specialized business verticals, including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation (CDMO) for sterile injectables, Contract Research, Development and Manufacturing Organisation (CRDMO), Generics, and Proprietary Novel Drugs.
What is the clearest takeaway from Q1 FY27?
During the quarter ended June 30, 2026, Jubilant Pharmova reported consolidated total revenue from operations of INR 2,229.4 crore and total income of INR 2,249.3 crore.
What drove revenue or demand?
Radiopharma led segment revenues at INR 1,022.1 crore for the quarter, supported by ongoing global demand for diagnostic and therapeutic nuclear medicine products.
What mattered most for margins or profitability?
Cost of materials consumed was INR 638.3 crore, purchases of stock-in-trade stood at INR 86.9 crore, and inventory changes reduced expenses by INR 23.5 crore.
What changed operationally beyond the headline numbers?
The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors on August 10, 2026.
What are the main pressure points disclosed for the quarter?
The Generics division faced profitability headwinds, registering a segment loss of INR 10.1 crore during the quarter.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Generics Turnaround: Monitor the operational performance and margin recovery of the Generics segment in subsequent quarters.
- 02
CDMO Margin Trajectory: Track segment result margins within the Sterile Injectables CDMO division relative to capital investments and facility asset growth.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.